Exclusive License Agreement between CymaBay Therapeutics, Inc. (as the licensor) and Kowa Pharmaceuticals America, Inc. (as the licensee) dated as of December 30, 2016Exclusive License Agreement • March 23rd, 2017 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”) dated as of this 30th day of December, 2016 (the “Effective Date”), is between CymaBay Therapeutics, Inc., a Delaware corporation having offices located at 7999 Gateway Blvd., Suite 130, Newark, California, U.S.A. (“CymaBay”), and Kowa Pharmaceuticals America, Inc., a Delaware corporation having offices located at 530 Industrial Park Blvd., Montgomery, Alabama, U.S.A. (“Kowa”). Each of CymaBay and Kowa may be referred to hereinafter individually as a “Party” and together as the “Parties.”
SECOND AMENDMENTSecond Amendment • March 23rd, 2017 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT (the “2nd Amendment”) is made and entered into effective as of December 23, 2016 (the “2nd Amendment Effective Date”) by and between CYMABAY THERAPEUTICS, INC., a Delaware corporation having a place of business at 7999 Gateway Blvd., Suite 130, Newark, CA 94560 USA (“CymaBay”), and DIATEX, INC., a corporation organized under the laws of Texas with a place of business at 105 Elm Spring Lane, San Antonio, TX 78231 (“DiaTex”). CymaBay and DiaTex may be referred to herein individually as a “Party”, and collectively as the “Parties.”
